Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $44.00.

Several equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday, July 17th. Guggenheim restated a “buy” rating and set a $43.00 target price on shares of Assembly Biosciences in a report on Thursday, May 28th. Wall Street Zen lowered Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research note on Monday, May 4th. Finally, Mizuho set a $45.00 price target on Assembly Biosciences and gave the company an “outperform” rating in a report on Monday, June 15th.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in shares of Assembly Biosciences by 6,382.7% during the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares in the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Assembly Biosciences in the fourth quarter valued at approximately $147,000. Acadian Asset Management LLC increased its holdings in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,823 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in shares of Assembly Biosciences in the fourth quarter valued at approximately $228,000. Finally, Virtus Investment Advisers LLC bought a new position in Assembly Biosciences in the 4th quarter worth approximately $251,000. 19.92% of the stock is owned by institutional investors.

Assembly Biosciences Trading Up 10.0%

NASDAQ:ASMB opened at $32.95 on Friday. Assembly Biosciences has a 1 year low of $20.23 and a 1 year high of $39.71. The firm has a 50 day moving average of $26.09 and a 200-day moving average of $27.38. The stock has a market capitalization of $523.58 million, a P/E ratio of 32.30 and a beta of 1.10.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.52. The business had revenue of $13.37 million for the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. As a group, analysts forecast that Assembly Biosciences will post 1.9 EPS for the current fiscal year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.